TABLE OF CONTENTS

• Description p.1
• Editorial Board p.1
• Guide for Authors p.3

DESCRIPTION

F&S Science, part of the Fertility and Sterility family of journals, publishes peer-reviewed original scientific articles in basic, laboratory, and translational research relevant to reproductive endocrinology, reproductive disorders, embryology, developmental biology, gonadal function, gamete biology, stem cell biology, urology, pathophysiology, immunology, genetics/epigenetics, contraception, fertility preservation, and menopause that has strong potential to transform clinical practice.

F&S Science accepts original research and occasional editorials. F&S Science does not accept systematic reviews, meta-analyses, critical analytic reviews of published literature, surveys, or case reports.

EDITORIAL BOARD

Editor-in-Chief
William Catherino, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States

Associate Editor
Nathan Treff, Rutgers School of Dental Medicine, Newark, New Jersey, United States

Editorial Board
Mohamed Aboulghar, Cairo University, Giza, Egypt
David Adamson, Palo Alto Medical Foundation, Santa Clara, California, United States
Paula Amato, Oregon Health & Science University, Portland, Oregon, United States
Mats Brännström, University of Gothenburg, Gothenburg, Sweden
Jorge E. Chavarro, Harvard University T H Chan School of Public Health, Boston, Massachusetts, United States
Young Min Choi, Seoul National University College of Medicine, Seoul, Korea, Republic of
Pierre Comizzoli, Smithsonian's National Zoo & Conservation Biology Institute, Washington, District of Columbia, United States
Michael H. Dahan, McGill University, Montreal, Quebec, Canada
Alice D. Domar, Harvard Medical School, Boston, Massachusetts, United States
Jacques Donnez, Research Society for Infertility, Brussels, Belgium
Michael L. Eisenberg, Stanford University School of Medicine, Stanford, California, United States
Bart Fauser, Utrecht University, Utrecht, Netherlands
Idhaliz Flores, University of Puerto Rico, Ponce School of Medicine, Puerto Rico, US Minor Outlying Islands
Elizabeth Ginsburg, Brigham and Women's Hospital, Boston, Massachusetts, United States
Linda C. Guidice, University of California San Francisco, San Francisco, California, United States
Emily S. Jungheim, Northwestern University - Chicago, Illinois, United States
Omid Khorram, The Lundquist Institute, Torrance, California, United States
Efstratios Kolibianakis, Aristotle University of Thessaloniki, Thessaloniki, Greece
Artur Ludwin, Jagiellonian University in Krakow, Krakow, Poland
Erica Marsh, University of Michigan Medical School, Ann Arbor, Michigan, United States
Robert John Norman, The University of Adelaide, Adelaide, South Australia, Australia
Lubna Pal, Yale University School of Medicine, New Haven, Connecticut, United States
Firuza Parikh, Jaslok Hospital and Research Centre, Mumbai, India
Felice Petraglia, University of Florence, Firenze, Italy
Catherine Racowsky, Brigham and Women's Hospital Department of Obstetrics and Gynecology, Boston, Massachusetts, United States
João Ramalho-Santos, University of Coimbra, Coimbra, Portugal
Ranjith Ramasamy, University of Miami, Coral Gables, Florida, United States
Paolo Rinaudo, University of California San Francisco, San Francisco, California, United States
James Segars, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Emri Seli, Yale University School of Medicine, New Haven, Connecticut, United States
Elizabeth Stewart, Mayo Clinic Rochester, Rochester, Minnesota, United States
H. Irene Su, University of California San Diego, La Jolla, California, United States
Hugh Taylor, Yale University School of Medicine, New Haven, Connecticut, United States
Bradley J. Van Voorhis, University of Iowa Roy J and Lucille A Carver College of Medicine, United States
Monica Vazquez-Levin, National Scientific and Technical Research Council, Buenos Aires, Argentina
GUIDE FOR AUTHORS

Only those manuscripts which are original, have not been published elsewhere, and are not currently being considered for inclusion in another publication will be considered for publication in F&S Science. Authors are advised to keep a copy of all manuscripts submitted.

All manuscripts will be evaluated by peer reviewers who will remain anonymous. Selection of the peer reviewers is at the sole discretion of the F&S Science editors. The editors and reviewers do not disclose any information about a manuscript or its review. If revisions are required, authors are asked to return the revised manuscripts within 40 days for the first revision, and within 30 days for any subsequent revisions. Please notify the editorial office if additional time is needed or if you choose not to submit a revision.

Authors are strongly encouraged to limit article length to 4,000 words for effective and efficient communication. If substantial merit would be gained from increasing the number of words in an article, longer submissions may be considered for publication. There is no limit to the total number of figures and tables. Article length does not include the running title, title page, capsule, abstract, or references.

If you wish, you may include expanded discussion of the materials and methods section, or additional figures or tables, as supplemental material. Please indicate in your cover letter which sections are intended to be supplemental material. Title any supplemental figures or tables as "Supplemental figure 1," and so on.

CONTACT INFORMATION

All correspondence regarding submitted manuscripts will be handled via e-mail through EM. Send all other correspondence to:

F&S Science
E: fertstert@asrm.org

BEFORE YOU BEGIN

ETHICS IN PUBLISHING

Authors

Conditions of Authorship
Authors should have made significant conceptual, intellectual, experimental, and analytical contributions to the research, as well as having participated in writing and revising the manuscript. Each author should have participated sufficiently in the work to take public responsibility for its content.
Honorary authorship (i.e., not adhering to the conditions of authorship and, none-the-less, being granted authorship) is not permitted.
All authors must sign the Statement of Authorship (typed or printed name is not acceptable) and include the form on initial submission.

Responsibilities of Authors
Authors must describe the research in sufficient detail such that others could repeat it. Written, informed consent under protocols approved by an institutional or local review board or approved animal protocols are essential if the research involves human or animal subjects, respectively. This information should be stated in the manuscript and the protocol number or exempt status of approved protocols should be stated in the manuscript at the time of submission for review. Authors of clinical trials are required to prospectively register their trial with one of the ICMJE-recognized trial registries (5).
Selective reporting of data is inappropriate, especially if unreported data are in disagreement with the findings of the selectively reported data. In accordance with the ICJME, Fertility and Sterility Science supports publication of important hypotheses that did not achieve statistical significance.
Authors should cite publications in the literature that are relevant to the uniqueness of the research and should including publications by others, as well as of their own research group.
Previous publication of a preliminary report on the data is permissible, if this is stated clearly in a footnote in the manuscript.

**SCIENTIFIC MISCONDUCT**

Definition: The DHHS Office of Research Integrity defines plagiarism, fabrication, and falsification.

The ASRM accepts these definitions and considers them to constitute scientific misconduct. Additional unethical behavior that comprises scientific misconduct includes: submission of results from animal or clinical research that was conducted without appropriate approval and written, informed consent; duplicate publication; and honorary authorship. Research misconduct occurs when results are falsified, fabricated or plagiarized. The actions are willful or intentional, although the actual definition of misconduct varies somewhat by country. This can occur at various times during the process of proposing, performing or reviewing research. Differences of opinion or honest errors do not constitute misconduct.

**Fabrication:** Data, results or recording or reporting information that does not exist.

**Falsification:** Changing research materials, equipment or processes; omission of data or results. As a consequence, the research is not accurately represented in the research records.

**Plagiarism:** Using another person's words, ideas, results, and processes without giving credit to them. Plagiarism includes the theft of intellectual property, ideas or methods such as the use of information gained by personal communication, or during a grant or manuscript review. Plagiarism also includes the direct textual copying of another person's work. Direct copying of 100-250 words constitutes plagiarism. Authorship disputes are not included in this definition. Citation plagiarism is the failure to credit others with prior discoveries and is extremely common. Self-plagiarism can include multiple publications of the same manuscript in different journals or books.

**Submission without animal or human subjects oversight approvals.** Any manuscript submitted without proof of animal or human subjects approval by institutional or local IRBs will not be reviewed and will be returned to the authors.

**Duplicate publication.** Duplicate publication can take several forms:

Duplicate Publication with other journals. On occasion ASRM journals may decide to publish an article simultaneously with another journal, e.g., with consensus statements from consensus conferences. Such intention on the part of the Editor-In-Chief should be discussed with the Publications Committee immediately after the two journals have had discussion so that Publications Committee members can assess the appropriateness of such joint publications and approve or disapprove.

Publication of identical data. The ASRM considers that disclosure, citing the original publication, and obtaining permission are essential. Without all of these, publication of identical data is inappropriate and not permissible.

"Salami" publications. Dividing data, analysis, and presentation into "minimally publishable units" is a slippery slope, and can be used to extend one data set over several manuscripts. While this may be acceptable for clarity of presentation and focus on specific outcomes in different manuscripts, a motivation may also be to increase the publication list in an author's CV. The latter is unethical and unacceptable. Therefore, please acknowledge in your cover letter any similar publications or submitted manuscripts.

**Partial publication**

Partial presentation of data in another medium (e.g., on a website) does not necessarily preclude publication in F&S Science, but acknowledgment of the previous presentation is required, along with identification of the source (e.g., the URL of the website). Content cannot be copied verbatim from the previous presentation, as that would constitute self-plagiarism, but must be rewritten to comply with journal standards.

**Investigation of scientific misconduct.** The journal follows COPE guidelines. All cases of suspected misconduct will be investigated initially by the Editor-In-Chief and the Publications Committee of the American Society for Reproductive Medicine to determine if the evidence of misconduct is sufficient to proceed with a formal inquiry. If so, the author will be notified in writing of the allegations, and will be asked to provide information useful to the investigation, including access to all original data, notes, and copies of prior publications. The author's institution may be contacted, as well. Processing and publication of the manuscript will be delayed while the matter is resolved. Confidentiality will be
maintained and care taken to protect the rights and reputations of all concerned. The final decision on disposition of the paper and any sanctions against the author will be made by the Editor-In-Chief in concert with the Publications Committee.

Potential sanctions include, but may not be limited to: rejection of a manuscript in process; a letter of reprimand to the author, copied to the author's institution; and correction or retraction of the manuscript, including a statement in the print issue detailing the nature of the misconduct.

**Reviewers.** Reviewers have the responsibility to objectively and fairly review the manuscript. If there is a conflict of interest or if the reviewer does not have the requisite expertise, then the manuscript should be immediately returned to the Editor for reassignment. Strict confidentiality is required during the review process. If any portion of a manuscript is shared before the review is completed and before acceptance and publication, written consent of the authors is required.

**Conflict of Interest**
All authors must disclose any financial and personal relationships with other people or organizations that could be perceived to inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. See also [https://www.elsevier.com/conflictsofinterest](https://www.elsevier.com/conflictsofinterest). Further information and an example of a Conflict of Interest form can be found at: [http://icmje.org/coi_disclosure.pdf](http://icmje.org/coi_disclosure.pdf).

**Submission declaration and verification**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

**Authorship**
To meet the criteria for authorship, in accordance with the *F&S Science* instructions for authors, all authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, AND (2) drafting the article or revising it critically for important intellectual content, AND (3) final approval of the version to be submitted, AND (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Changes to authorship**
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the Journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason
for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they
agree with the addition, removal or rearrangement. In the case of addition or removal of authors,
this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of
authors after the manuscript has been accepted. While the Editor considers the request, publication
of the manuscript will be suspended. If the manuscript has already been published in an online issue,
any requests approved by the Editor will result in a corrigendum.

Reporting clinical trials
Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript
submission, authors must provide the CONSORT checklist accompanied by a flow diagram that
illustrates the progress of patients through the trial, including recruitment, enrollment, randomization,
withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT
checklist and template flow diagram are available online.

Registration of clinical trials
Registration in a public trials registry is a condition for publication of clinical trials in this journal
in accordance with International Committee of Medical Journal Editors recommendations. Trials
must register at or before the onset of patient enrolment. The clinical trial registration number
should be included at the end of the abstract of the article. A clinical trial is defined as any
research study that prospectively assigns human participants or groups of humans to one or more
health-related interventions to evaluate the effects of health outcomes. Health-related interventions
include any intervention used to modify a biomedical or health-related outcome (for example drugs,
surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care
changes). Health outcomes include any biomedical or health-related measures obtained in patients or
participants, including pharmacokinetic measures and adverse events. Purely observational studies
(those in which the assignment of the medical intervention is not at the discretion of the investigator)
will not require registration.

The ICMJE accepts registration in the following registries:

http://www.anzctr.org.au

http://www.clinicaltrials.gov

http://www.ISRCTN.org

http://www.umin.ac.jp/ctr/index/htm

http://www.trialregister.nl


In addition to the above registries, starting in June 2007 the ICMJE will also accept registration
in any of the primary registries that participate in the WHO International Clinical Trials Portal (see
http://www.who.int/ictrp/network/primary/en/index.html). Because it is critical that trial registries
are independent of for-profit interests, the ICMJE policy requires registration in a WHO primary
registry rather than solely in an associate registry, since for-profit entities manage some associate
registries. Trial registration with missing or uninformative fields for the minimum data elements is
inadequate even if the registration is in an acceptable registry.

Copyright
Upon acceptance of an article, authors will be asked to complete a "Journal Publishing Agreement“ (see
more information on this). An e-mail will be sent to the corresponding author confirming receipt of
the manuscript together with a "Journal Publishing Agreement“ form or a link to the online version
of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal
circulation within their institutions. Permission of the Publisher is required for resale or distribution
outside the institution and for all other derivative works, including compilations and translations. If
excerpts from other copyrighted works are included, the author(s) must obtain written permission
from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for
use by authors in these cases. For gold open access articles: Upon acceptance of an article, authors will be asked to complete an "Exclusive License Agreement" (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information.]

**Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

**Open access**

This journal offers authors a choice in publishing their research:

**Subscription**

Articles are made available to subscribers as well as developing countries and patient groups through our [universal access programs](https://www.elsevier.com/universalaccess). No open access publication fee payable by authors. The Author is entitled to post the accepted manuscript in their institution's repository and make this public after an embargo period (known as green Open Access). The [published journal article](https://www.elsevier.com/publishedjournal) cannot be shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-reviewed research in journal publications. The embargo period for this journal can be found below.

**Gold open access**

Articles are freely available to both subscribers and the wider public with permitted reuse. A gold open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For gold open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](https://creativecommons.org/licenses):

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)**

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 3500**, excluding taxes. There is a **50%** discount off the open access publication fee for [members of the ASRM](https://www.elsevier.com/membersofasrm). Learn more about Elsevier's pricing policy: [https://www.elsevier.com/openaccesspricing](https://www.elsevier.com/openaccesspricing).

**Green open access**

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [open access page](https://www.elsevier.com/openaccess) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more.](https://www.elsevier.com/openaccess)

This journal has an embargo period of 12 months.
**Language (usage and editing services)**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

**Submission**
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

**Submit your article**

**PREPARATION**

**Use of word processing software**
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**LaTeX**
You are recommended to use the Elsevier article class elsarticle.cls to prepare your manuscript and BibTeX to generate your bibliography.
Our LaTeX site has detailed submission instructions, templates and other information.

**Article structure**

**Subdivision - unnumbered sections**
Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

**Introduction**
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

**Material and methods**
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

**Results**
Results should be clear and concise.

**Discussion**
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

**Conclusions**
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.
Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Structured abstract

A structured abstract, by means of appropriate headings, should provide the context or background for the research and should state its purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), and principal conclusions. It should emphasize new and important aspects of the study or observations.

Key words

Immediately after the abstract, provide 3-5, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help or writing assistance or proofreading the article, etc.).

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Artwork

**Electronic artwork**

**General points**

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.
- Ensure that color images are accessible to all, including those with impaired color vision.

A detailed [guide on electronic artwork](https://www.example.com) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

**Formats**
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format. Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
- EPS (or PDF): Vector drawings, embed all used fonts.
- TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
- TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
- TIFF (or JPEG): Combinations bitmapped line/halftone (color or grayscale), keep to a minimum of 500 dpi.

**Please do not:**
- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

**Color artwork**
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites). Further information on the preparation of electronic artwork.

**Figure captions**
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

**Tables**
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

**References**

**Citation in text**
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

**Web references**
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

**Data references**
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

**Reference style**
References follow style of "Uniform Requirements" ([http://www.nlm.nih.gov/bsd/uniform_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)).

**Examples:**


Reference list

References are numbered consecutively, with Arabic numerals, in the order of text citation, including citations in figure legends and tables at first mention in text. List up to six authors, followed by a comma and et al. Journal article titles are initial cap/lower case. Use lower case letter after colon in journal article title. Abbreviate journal names according to the current Index Medicus. Do not use an ampersand in journal names. Delete issue number in parentheses after volume. Page ranges use only the numbers that change.

Journal abbreviations source

Journal names should be abbreviated according to the List of Title Word Abbreviations.
**Video**
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file’s content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply ‘stills’ with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Data visualization**
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplemental data**
Elsevier accepts electronic supplemental material to support and enhance your scientific research. Supplemental files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips, and more. Supplemental files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at https://www.elsevier.com/artworkinstructions.

**Research data**
In accordance with data set transparency goals, submission of sequencing, polymorphisms, conformation, and "-omic" data-sets are to be submitted to a public repository. Links shall be included in the manuscript for accession by the reader of such data-sets used. For example, microarray and similar genomic data shall be submitted to the Gene Expression Omnibus (GEO) repository.

Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).
**Mendeley Data**

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. Before submitting your article, you can deposit the relevant datasets to **Mendeley Data**. Please include the DOI of the deposited dataset(s) in your main manuscript file. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](https://www.mendeley.com/data).

**Submission Checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

1. **One author has been designated as the corresponding author with contact details:** E-mail address
2. Full postal address
3. Phone numbers

4. All necessary files have been uploaded, and contain:
   - Keywords
   - All figure captions
   - All tables (including title, description, footnotes)
   - Appropriate completed study-type checklist (i.e., STROBE, STREGA, CONSORT, STARD, PRISMA)
   - Statement of Authorship
   - Form ICMJE Conflict of Interest Disclosure Form for each author

5. **Further considerations:** Manuscript has been spell-checked and grammar-checked
   - References are in the correct format for the journal
   - All references mentioned in the Reference list are cited in the text, and vice versa
   - Permission has been obtained for use of copyrighted material from other sources (including the Web). Provide copies of the permissions for journal records.
   - Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print. If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at [https://service.elsevier.com](https://service.elsevier.com).

**AFTER ACCEPTANCE**

**Proofs**

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or a link will be provided in the e-mail so that authors can download the files themselves. To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download the free Adobe Reader, version 9 (or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the [Adobe site](https://www.adobe.com/products/acrobat/professional.html).

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and scan the pages and return via e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**

Offprints may be ordered from Elsevier Inc.

**Standards For Reporting Research**

Incomplete or inadequate reporting of research complicates the identification of the strengths and weaknesses of the studies reported in the medical literature. To solve this problem, several sets of guidelines have been developed in order to guarantee that the required information is available in a manuscript, to improve the accuracy and completeness of reporting of studies, and to allow readers to assess the potential for bias in the study (internal validity) and to evaluate its applicability to other environments (external validity).
Authors are strongly encouraged to consult the widely-accepted checklists below for each study type. Their application will increase the chances of acceptance by ensuring that important information will not be missed, producing a homogeneous and structured medical report, permitting fair and objective refereeing, and simplifying future corrections and revisions.

Reports of randomized trials: CONSORT
http://www.consort-statement.org/

Studies of diagnostic accuracy: STARD
http://www.equator-network.org/reporting-guidelines/stard/

Observational studies (cohort, case-control, or cross-sectional designs): STROBE
http://www.strobe-statement.org/

Genetic association: STREGA
http://www.equator-network.org/reporting-guidelines/strobo-strega/

Systematic review/meta-analysis: PRISMA
http://www.prisma-statement.org/